TIMELINE-RPT-Early signs of pushback over U.S. drug prices
May 28, 2014 at 07:00 AM EDT
May 28 (Reuters) - Gilead Sciences' $84,000 treatment for hepatitis C, Sovaldi, has broken the sales record for drug launches and caused a backlash among insurers concerned by the cost. Before the Sovaldi outcry, U.S. insurers and doctors made limited attempts to curb the rising cost of novel medicines.